NEW YORK (
CHANGE IN RATINGS
upgraded at Mizuho from Neutral to Buy, Mizuho said. $100 price target. Egypt sale is a positive sign.
rated new Neutral at Credit Suisse. Valuation call, based on a $30 price target.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Company also added to the Conviction List, with a $47 price target. See volume recovery and margin expansion.
upgraded at Leerink to Outperform. $56 price target. Survey suggests that the company could see new business as hospitals look to replace EMR vendors.
downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Estimates also cut. Acquisition should cut into earnings and the company will likely buy back fewer shares.
rated new Neutral at Goldman. Valuation call, based on a $35 price target.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. $21 price target. Company has lower earnings visibility.
upgraded at Janney from Neutral to Buy, Janney Montgomery said. $26 price target. Product pipeline is improving and the company appears to be selling well with Macy's.
downgraded at Oppenheimer from Outperform to Perform, Oppenheimer said. Seeing near-term negative dynamics in the display segment.
upgraded at BMO from Market Perform to Outperform, BMO Capital said. $37 price target. New analyst sees an attractive valuation.
upgraded at Oppenheimer from Underperform to Perform, Oppenheimer said. NOK purchase lifts an overhang.
Palo Alto Networks
downgraded at JMP from Outperform to Market Perform, JMP Securities said. Sales and support staff are impacting execution and market share gains.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $65 price target. Company should benefit from beer cost savings.
downgraded at Canaccord from Buy to Hold, Canaccord Genuity said. $59 price target. Company is facing gross margin headwinds.
STOCK COMMENTS / EPS CHANGES
estimates reduced at Raymond James through 2015, Raymond James said. Sell-through has likely been weak, despite several product launches. Market Perform rating.
estimates cut at Sterne Agee through 2015, Sterne Agee said. Industry sales trends have been weak. Buy rating and $55 price target.
numbers raised at UBS. GWRE earnings estimates were raised given momentum from sales force productivity and deal wins, said UBS. Price target is boosted to $52.
estimates increased at Lazard through 2014, Lazard Capital Markets said. Management remained positive about the DRAM market on a recent roadshow. Neutral rating.
estimates, target boosted at Leerink. Shares of PFE now seen reaching $28.50, according to Leerink Swann. Estimates also upped, given higher international Lyrica sales and cost cutting. Market Perform rating.
estimates reduced at Jefferies to reflect a modest equipment-related delivery delay on the Renaissance ship, said Jefferies. Price target is $42.
READ: 'My Biggest Work Mistake': 7 Career Confessions
added to Best Ideas List at Wunderlich. Company is ramping production, but trades at a discount to peers.
estimates, target raised at Oppenheimer. Shares of VZ now seen reaching $56, according to Oppenheimer. Estimates also increased, following the wireless buyout. Outperform rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.